DaTSCAN (Ioflupane I-123): Uses, Dosage & Side Effects
A diagnostic radiopharmaceutical for brain SPECT imaging used to detect loss of dopamine transporters in Parkinson's disease and Lewy body dementia
DaTSCAN (ioflupane I-123) is a diagnostic radiopharmaceutical used in conjunction with single-photon emission computed tomography (SPECT) imaging to visualize dopamine transporter (DAT) distribution in the brain. It is primarily used to help differentiate Parkinson's disease and Lewy body dementia from conditions with similar symptoms such as essential tremor or Alzheimer's disease. DaTSCAN is administered as a single intravenous injection in a hospital or specialized nuclear medicine facility and is intended solely for diagnostic use, not for treatment.
Quick Facts: DaTSCAN
Key Takeaways
- DaTSCAN is a diagnostic imaging agent, not a treatment. It helps doctors visualize dopamine transporter density in the brain using SPECT technology to support the clinical diagnosis of parkinsonian syndromes and Lewy body dementia.
- The procedure involves a single intravenous injection followed by SPECT imaging 3 to 6 hours later. Thyroid-blocking medication must be taken beforehand to prevent radioactive iodine uptake by the thyroid gland.
- Several medications, including certain antidepressants (SSRIs), bupropion, stimulants, and cocaine, can interfere with DaTSCAN results and may need to be discontinued before the scan.
- DaTSCAN is contraindicated in pregnancy and should not be used in children or adolescents under 18 years of age. Breastfeeding must be interrupted for at least 3 days after the procedure.
- The radiation exposure from DaTSCAN is low and is generally considered to be outweighed by the diagnostic benefit. The iodine-123 isotope has a half-life of approximately 13 hours and is rapidly eliminated from the body.
What Is DaTSCAN and What Is It Used For?
DaTSCAN contains the active substance ioflupane (123I), a radiopharmaceutical specifically designed for diagnostic imaging of the brain. It belongs to a group of medicines called radiopharmaceuticals, which contain a small, carefully controlled amount of radioactivity that allows specialized cameras to capture detailed images of internal body structures. DaTSCAN is approved by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) for clinical use in adults.
When DaTSCAN is injected intravenously, the active ingredient travels through the bloodstream and crosses the blood-brain barrier. It then accumulates preferentially in a specific region of the brain called the striatum (consisting of the caudate nucleus and putamen), where it binds with high affinity to presynaptic dopamine transporters (DAT) located on the terminals of dopaminergic neurons. These dopamine transporters are proteins that recycle dopamine back into nerve cells after it has been released, and their density reflects the integrity of the nigrostriatal dopaminergic pathway.
In healthy individuals, the SPECT scan shows a characteristic comma-shaped or crescent-shaped pattern of radiotracer uptake in the striatum on both sides of the brain. In patients with neurodegenerative conditions that damage dopamine-producing neurons, such as Parkinson's disease, multiple system atrophy (MSA), progressive supranuclear palsy (PSP), or corticobasal degeneration, the dopamine transporter density is reduced. This reduction is visible on the SPECT scan as decreased radiotracer uptake, often appearing as a dot-shaped or asymmetrically reduced pattern rather than the normal comma shape.
DaTSCAN is clinically indicated for two primary purposes. First, it is used to help differentiate essential tremor from parkinsonian syndromes (including idiopathic Parkinson's disease and other degenerative parkinsonisms). Essential tremor is a relatively benign condition where dopamine neurons are preserved, resulting in a normal DaTSCAN, whereas parkinsonian syndromes show reduced dopamine transporter uptake. Second, DaTSCAN is used as an adjunct to help distinguish probable Lewy body dementia from Alzheimer's disease. Patients with Lewy body dementia typically show reduced DAT uptake, while those with Alzheimer's disease generally have normal dopaminergic function.
It is important to understand that DaTSCAN is exclusively a diagnostic tool. It does not treat any condition and is not intended for monitoring disease progression or treatment response. The scan provides information about the state of the dopaminergic system at the time of the examination, but the results must always be interpreted by a qualified nuclear medicine physician in conjunction with the patient's complete clinical picture, including medical history, physical examination, and other diagnostic findings. An abnormal DaTSCAN does not by itself establish a specific diagnosis, as several different neurodegenerative conditions can produce similar patterns of reduced DAT uptake.
When DaTSCAN is administered, you are exposed to a small amount of ionizing radiation. The radiation dose from a standard DaTSCAN procedure (185 MBq injection) results in an effective dose of approximately 4.4 mSv, which is comparable to or less than the dose received during some common CT scans. The iodine-123 isotope used in DaTSCAN has a physical half-life of approximately 13.2 hours, meaning that the radioactivity decreases by half every 13 hours and is substantially eliminated from the body within a few days. Your doctor and nuclear medicine specialist will have determined that the diagnostic benefit of the scan outweighs the small risk associated with the radiation exposure.
What Should You Know Before Receiving DaTSCAN?
Contraindications
DaTSCAN must not be administered in certain circumstances. You should not receive this medication if you have a known allergy (hypersensitivity) to ioflupane or to any of the other ingredients in the solution, which include acetic acid, sodium acetate, ethanol, and water for injections. As with all radiopharmaceuticals containing iodinated compounds, allergic reactions including anaphylaxis are possible, although rare. Nuclear medicine departments are equipped to manage such reactions should they occur.
DaTSCAN is contraindicated during pregnancy. Radiopharmaceuticals carry a risk to the developing fetus due to radiation exposure. If there is any possibility that you could be pregnant, you must inform your nuclear medicine physician before the procedure. Alternative diagnostic methods that do not involve ionizing radiation should be considered in such cases.
Warnings and Precautions
Before receiving DaTSCAN, speak with your nuclear medicine physician about all aspects of your health. Special caution is advised in patients with moderate or severe kidney disease or liver disease, as these conditions may affect the elimination of the radiotracer and its metabolites from the body. Your doctor will weigh the diagnostic benefit against any potential risks in your specific situation.
Before receiving DaTSCAN, you will be given thyroid-blocking medication (typically potassium iodide tablets, potassium perchlorate, or Lugol's solution). This is essential to prevent your thyroid gland from absorbing free radioactive iodine-123 that may be released during the metabolism of ioflupane. You must take this medication as directed by your doctor, usually at least one hour before the injection. Failure to do so may result in unnecessary radiation exposure to your thyroid.
Adequate hydration is important both before and after the DaTSCAN procedure. You should drink plenty of water to ensure you are well hydrated, and you should urinate as frequently as possible during the first 48 hours after the injection. This helps to eliminate the radioactive substance from your body more quickly and reduces your overall radiation exposure. There are no dietary restrictions before or after the scan other than maintaining good hydration.
DaTSCAN results must be interpreted in the context of the full clinical picture. An abnormal scan indicates reduced dopamine transporter density but does not distinguish between different causes of dopaminergic neurodegeneration (for example, it cannot differentiate Parkinson's disease from MSA or PSP). Similarly, a normal scan does not completely rule out early-stage disease in rare cases. The scan results should always be considered alongside clinical symptoms, neurological examination, and other relevant investigations.
Children and Adolescents
DaTSCAN is not recommended for use in children and adolescents aged 0 to 18 years. The safety and efficacy of this product have not been established in the pediatric population. Parkinsonian syndromes and Lewy body dementia are predominantly conditions of older adults, and the clinical need for DaTSCAN imaging in young patients is extremely rare. If diagnostic imaging is considered necessary in a younger patient, the nuclear medicine physician will carefully assess whether the potential benefit justifies the radiation exposure.
Pregnancy and Breastfeeding
DaTSCAN must not be used during pregnancy. The radioactive nature of this product means that the developing fetus could be exposed to ionizing radiation, which carries potential risks for embryonic and fetal development. If you are of childbearing age, your nuclear medicine physician may require a pregnancy test before proceeding with the scan. If you suspect you might be pregnant, inform your doctor immediately so that alternative diagnostic approaches can be discussed.
If you are breastfeeding, your nuclear medicine physician may postpone the DaTSCAN examination or ask you to interrupt breastfeeding. It is not known with certainty whether ioflupane (123I) is excreted in human breast milk. As a precautionary measure, you must not breastfeed for at least 3 days after receiving DaTSCAN. During this period, express and discard your breast milk at regular intervals to maintain milk production. You should use formula milk for your baby during this time. After 3 days, the radioactivity will have diminished sufficiently for breastfeeding to resume safely.
Driving and Operating Machinery
DaTSCAN has no known effect on the ability to drive or operate machinery. The injection itself does not cause sedation, drowsiness, or any impairment of cognitive or motor function. You may drive yourself to and from the appointment unless your underlying medical condition prevents you from doing so safely.
DaTSCAN solution contains alcohol (ethanol) at 5% by volume. Each dose contains up to 197 mg of alcohol, which is approximately equivalent to 5 ml of beer or 2 ml of wine. This small amount of alcohol may be harmful for people with alcohol use disorder and should be taken into consideration for patients with liver disease or epilepsy. Inform your doctor if any of these conditions apply to you.
How Does DaTSCAN Interact with Other Drugs?
DaTSCAN works by binding to dopamine transporters (DAT) in the brain. Any medication or substance that also binds to these transporters can compete with DaTSCAN for binding sites, potentially reducing the amount of radiotracer uptake visible on the SPECT scan. This competition could lead to a false-normal result (where the scan appears normal despite actual dopaminergic neurodegeneration) or could reduce the quality of the diagnostic image. It is therefore essential to inform your nuclear medicine physician about all medications, supplements, and substances you are taking or have recently taken.
Importantly, many commonly used medications for Parkinson's disease, including levodopa, dopamine agonists (pramipexole, ropinirole, rotigotine), MAO-B inhibitors (selegiline, rasagiline), and COMT inhibitors (entacapone), do not significantly affect DaTSCAN binding and generally do not need to be discontinued before the scan. This is because these drugs act on dopamine receptors or dopamine metabolism rather than directly on the dopamine transporter.
Major Interactions
| Medication | Category | Effect on DaTSCAN |
|---|---|---|
| Bupropion | Antidepressant / Smoking cessation | Binds to DAT; may reduce radiotracer uptake and produce misleading results |
| Cocaine | Stimulant (also used as local anesthetic in nasal surgery) | Strong DAT binding; significantly reduces DaTSCAN uptake |
| Methylphenidate, Dexamphetamine | ADHD / Narcolepsy treatment | Compete for DAT binding sites; may alter scan results |
| Amphetamines | Stimulant | Reduce DAT availability; can produce inaccurate readings |
| Phentermine | Appetite suppressant (obesity treatment) | Interacts with DAT; may interfere with scan interpretation |
Minor Interactions
| Medication | Category | Effect on DaTSCAN |
|---|---|---|
| Sertraline, Paroxetine, Citalopram, Escitalopram, Fluoxetine, Fluvoxamine | SSRI Antidepressants | Some SSRIs have affinity for DAT; clinical significance varies. Your doctor may advise temporary discontinuation. |
| Modafinil | Wakefulness-promoting agent (narcolepsy, shift-work disorder) | Has some DAT binding affinity; may marginally affect scan quality |
| Codeine | Opioid analgesic / Cough suppressant | May have minor effects on DAT imaging; discuss with your doctor |
If you are taking any of the medications listed above, your nuclear medicine physician may ask you to stop them for a period of time before the DaTSCAN procedure. The required washout period depends on the specific medication and its half-life. For example, fluoxetine has a very long half-life and may need to be stopped several weeks in advance. Never stop any prescribed medication without first consulting your treating physician, as abrupt discontinuation can cause withdrawal symptoms or worsen your underlying condition. Your doctors will work together to determine the safest approach.
What Is the Correct Dosage of DaTSCAN?
DaTSCAN is a radiopharmaceutical that is handled, prepared, and administered exclusively by authorized personnel in nuclear medicine departments of hospitals or specialized imaging centers. Unlike conventional medicines that patients take at home, DaTSCAN administration follows strict regulations governing the use of radioactive materials. You do not need to handle the product yourself, and the correct dose will be carefully calculated and administered by the nuclear medicine team.
Adults
Standard Dose for Adults
Recommended activity: 111 to 185 MBq (megabecquerels), administered as a single intravenous injection
Route: Slow intravenous injection, typically into a vein in the arm
Imaging time: SPECT scan performed 3 to 6 hours after injection
Pre-treatment: Thyroid-blocking agent (potassium iodide or similar) must be administered at least 1 hour before the DaTSCAN injection
The exact dose within the 111-185 MBq range is determined by the nuclear medicine physician based on the patient's body weight, the specifications of the SPECT camera being used, and the time planned between injection and imaging. A single injection is sufficient for the diagnostic procedure, and repeat dosing is not normally necessary. The entire volume of injection typically ranges from 2.5 to 5 ml, delivered slowly into a peripheral vein.
Elderly Patients
No dose adjustment is required for elderly patients. The standard dose of 111 to 185 MBq applies regardless of age in adults. Since the primary clinical indications for DaTSCAN (parkinsonian syndromes and Lewy body dementia) are predominantly conditions of older adults, the majority of patients receiving DaTSCAN are in this age group, and extensive clinical experience supports the safety and efficacy of the standard dose in elderly populations.
Children
DaTSCAN is not recommended for use in children and adolescents aged 0 to 18 years. The safety and efficacy in this population have not been established. The conditions for which DaTSCAN is indicated are overwhelmingly adult-onset disorders.
The DaTSCAN Procedure Step by Step
Understanding the complete DaTSCAN procedure can help alleviate anxiety and ensure the best possible diagnostic outcome. The procedure generally follows a standardized protocol that has been refined over years of clinical practice according to guidelines published by the European Association of Nuclear Medicine (EANM) and the Society of Nuclear Medicine and Molecular Imaging (SNMMI).
- Preparation: You will be asked to take a thyroid-blocking medication (such as potassium iodide tablets) at least one hour before the injection. This protects your thyroid from absorbing free radioactive iodine. You should also be well hydrated.
- Injection: A nuclear medicine technologist or physician will inject the DaTSCAN solution slowly into a vein in your arm. The injection takes only a few minutes and feels similar to a normal blood draw or intravenous line placement.
- Waiting period: After the injection, you will wait 3 to 6 hours to allow the radiotracer to travel through your bloodstream, cross the blood-brain barrier, and accumulate in the dopamine transporters of your striatum. During this waiting period, you can eat, drink, and move around normally.
- SPECT imaging: You will lie on a scanning table, and a specialized gamma camera will rotate around your head to capture images. You must remain as still as possible during the scan, which typically takes 30 to 45 minutes. The camera does not produce radiation; it only detects the gamma rays emitted by the radiotracer in your brain.
- After the scan: You can resume normal activities immediately after the imaging is complete. You should continue to drink plenty of fluids and urinate frequently for the next 48 hours to help eliminate the radioactive material from your body. No special shielding or isolation is required.
Overdose
Because DaTSCAN is administered by qualified medical professionals under controlled conditions, overdose is extremely unlikely. In the event that a dose exceeding the intended amount is accidentally administered, the nuclear medicine physician will recommend increased fluid intake and frequent urination to accelerate the elimination of the radiotracer from the body. The iodine-123 in DaTSCAN naturally loses its radioactivity over time (half-life approximately 13 hours), so any residual radioactivity will diminish on its own. No specific antidote is required or available. You should follow any hygiene precautions regarding urination as instructed by your medical team.
What Are the Side Effects of DaTSCAN?
Like all medicines, DaTSCAN can cause side effects, although not everyone who receives it will experience them. The majority of adverse reactions reported in clinical trials and post-marketing surveillance have been mild and transient, resolving without specific treatment. Since DaTSCAN is administered as a single dose for diagnostic purposes, the exposure period is limited, and the risk of cumulative or long-term side effects is very low.
The side effects of DaTSCAN can be categorized by frequency based on data from clinical studies and post-marketing reports. The small amount of radioactivity administered is substantially below the threshold associated with deterministic radiation effects, and the stochastic risk (very small theoretical increase in lifetime cancer risk) is considered to be far outweighed by the diagnostic benefit of the procedure.
Common
May affect up to 1 in 10 patients
- Headache
Uncommon
May affect up to 1 in 100 patients
- Increased appetite
- Dizziness or vertigo
- Taste disturbances (dysgeusia)
- Nausea
- Dry mouth
- Tingling or crawling sensation on the skin (formication)
- Intense pain or burning at the injection site (particularly if injected into a small vein)
Not Known
Frequency cannot be estimated from available data
- Hypersensitivity (allergic reactions)
- Shortness of breath (dyspnea)
- Skin flushing (erythema)
- Itching (pruritus)
- Skin rash
- Hives (urticaria)
- Excessive sweating (hyperhidrosis)
- Vomiting
- Low blood pressure (hypotension)
- Sensation of warmth
Although extremely rare, severe allergic reactions (anaphylaxis) can occur with any radiopharmaceutical. Seek immediate medical help if you experience sudden difficulty breathing, swelling of the face, lips, tongue, or throat, severe dizziness, rapid heartbeat, or widespread skin rash shortly after the injection. Nuclear medicine departments are equipped with emergency resuscitation equipment and medications to manage such reactions.
The injection site may occasionally cause discomfort, particularly if the solution is inadvertently injected into a small peripheral vein. This can manifest as a brief burning sensation or localized pain, which typically resolves within minutes to hours. If significant injection site irritation persists, inform the nuclear medicine staff so they can provide appropriate local care.
The small amount of radioactivity introduced into your body by DaTSCAN will diminish naturally over the following days. The effective half-life of iodine-123 in the body is approximately 13 hours, meaning that after about 3 days, the radioactivity has been reduced to negligible levels. You do not need to take any special precautions regarding contact with other people, although maintaining good hydration and frequent urination during the first 48 hours will help accelerate the clearance of the radiotracer.
How Should DaTSCAN Be Stored?
As a radiopharmaceutical product, DaTSCAN is stored under highly controlled conditions within nuclear medicine departments and is never dispensed to patients for home use. The storage, handling, transportation, and disposal of DaTSCAN are governed by national and international regulations on radioactive materials, and all personnel involved in these processes must be appropriately qualified and authorized.
The product must be stored at a temperature not exceeding 25°C (77°F) and must not be frozen. It should be kept out of the sight and reach of children, stored within appropriate radiation shielding, and used before the expiration date stated on the packaging. The hospital staff are responsible for ensuring that the product is stored correctly and that it is not used after its expiration date. Due to the relatively short half-life of iodine-123 (approximately 13 hours), the shelf life of DaTSCAN is limited, and fresh product is typically ordered specifically for each scheduled patient scan.
Disposal of unused DaTSCAN or waste material derived from its use must follow institutional procedures for radioactive waste management, in compliance with local, national, and international regulations. Contaminated materials such as syringes, vials, and protective equipment are handled as radioactive waste and disposed of through authorized waste management channels.
What Does DaTSCAN Contain?
Active Ingredient
The active substance in DaTSCAN is ioflupane (123I), also known as 123I-FP-CIT (N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropane). Each milliliter of solution contains ioflupane (123I) 74 MBq at the reference time, with the actual amount of ioflupane present being extremely small (0.07 to 0.13 micrograms per milliliter). The iodine-123 isotope is produced in a cyclotron facility and has a gamma photon energy of 159 keV, which is optimal for detection by SPECT gamma cameras.
Inactive Ingredients (Excipients)
- Acetic acid: Used as a pH buffer to maintain the stability and proper acidity of the solution
- Sodium acetate: Serves as a co-buffer to maintain solution pH within the required range
- Ethanol (5% by volume): Acts as a co-solvent to keep the active substance in solution. Each dose contains up to 197 mg of alcohol.
- Water for injections: The primary solvent, meeting pharmacopeial standards for injectable preparations
Appearance and Packaging
DaTSCAN is a clear, colorless solution for injection supplied in 10 ml colorless glass vials. Each vial contains either 2.5 ml or 5 ml of solution and is sealed with a rubber stopper and aluminum crimp cap. The glass vials meet the specifications required for pharmaceutical containers that hold radioactive materials. The product is shipped within appropriate radiation shielding to protect handlers during transportation, and each shipment includes documentation of the radioactive content and calibration time.
DaTSCAN is manufactured by GE Healthcare B.V. (Eindhoven, Netherlands), a subsidiary of GE HealthCare Technologies Inc., one of the world's leading providers of medical imaging products and radiopharmaceuticals. The product has been approved for clinical use in the European Union since 2000 and in the United States since 2011, with extensive post-marketing surveillance data supporting its safety and diagnostic efficacy.
Frequently Asked Questions About DaTSCAN
A DaTSCAN is a specialized brain imaging procedure that uses a radioactive tracer called ioflupane (123I) to visualize dopamine transporters in the brain. It is performed to help doctors differentiate between conditions that cause similar symptoms, particularly to distinguish Parkinson's disease and Lewy body dementia from essential tremor and other movement disorders. The scan reveals whether there is a loss of dopamine-producing nerve cells in the striatum, a key brain area involved in movement control.
DaTSCAN is generally safe when performed by qualified nuclear medicine professionals. The radiation exposure from a standard DaTSCAN procedure is approximately 4.4 mSv, which is comparable to or less than some common CT procedures. The iodine-123 isotope has a half-life of approximately 13 hours, meaning the radioactivity decreases rapidly and is largely eliminated from the body within a few days. Your doctor will have determined that the diagnostic benefit outweighs the small risk associated with the radiation dose.
The complete DaTSCAN procedure typically takes most of a day. The injection itself takes only a few minutes, but the imaging is performed 3 to 6 hours later to allow the radiotracer to accumulate in the brain. The actual SPECT scan takes approximately 30 to 45 minutes, during which you must lie still. Before the injection, you will also receive thyroid-blocking medication and should be well hydrated. You can eat, drink, and move around normally during the waiting period between injection and scan.
Several medications can interfere with DaTSCAN results and may need to be discontinued before the procedure. These include certain antidepressants (SSRIs such as sertraline, paroxetine, fluoxetine), bupropion, stimulants (methylphenidate, amphetamines), modafinil, phentermine, and cocaine. Importantly, levodopa and most dopamine agonists used to treat Parkinson's disease do not need to be stopped. Never discontinue any prescribed medication without first consulting your treating physician.
DaTSCAN cannot definitively diagnose Parkinson's disease on its own. It detects the loss of dopamine transporters in the brain, which occurs in several conditions including Parkinson's disease, multiple system atrophy, progressive supranuclear palsy, and Lewy body dementia. An abnormal DaTSCAN confirms dopaminergic degeneration, while a normal scan makes Parkinson's disease very unlikely. The results must be interpreted alongside your complete clinical picture, medical history, and neurological examination.
The DaTSCAN injection is similar to a standard blood draw or intravenous line insertion. You may feel a brief pinch or sting when the needle is inserted into the vein. Some patients experience a mild burning sensation during the injection, but this is typically brief and resolves quickly. If the solution is injected into a very small vein, the discomfort may be slightly more noticeable. The SPECT scan itself is completely painless; it simply involves lying still while the camera captures images around your head.
References
- 1 European Medicines Agency (EMA). DaTSCAN Summary of Product Characteristics. Last updated 2024. Available at: ema.europa.eu
- 2 U.S. Food and Drug Administration (FDA). DaTSCAN (Ioflupane I 123 Injection) Prescribing Information. Approved 2011, revised 2023.
- 3 Darcourt J, Booij J, Tatsch K, et al. EANM procedure guidelines for brain neurotransmission SPECT using 123I-labelled dopamine transporter ligands. Eur J Nucl Med Mol Imaging. 2010;37(2):443-450.
- 4 Djang DSW, Janssen MJR, Bohnen N, et al. SNM practice guideline for dopamine transporter imaging with 123I-ioflupane SPECT 1.0. J Nucl Med. 2012;53(1):154-163.
- 5 Booij J, Dubroff J, Pryma D, et al. Diagnostic performance of the visual reading of 123I-ioflupane SPECT images with or without quantification in patients with movement disorders or dementia. J Nucl Med. 2017;58(11):1821-1826.
- 6 McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88-100.
- 7 Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015;30(12):1591-1601.
- 8 World Health Organization (WHO). WHO Model List of Essential Medicines. 23rd List, 2023.
Medical Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, which includes licensed physicians specializing in nuclear medicine, neurology, and clinical pharmacology. All content follows the GRADE evidence framework and adheres to international guidelines from the EMA, FDA, EANM, and SNMMI.
All medical information has been reviewed for accuracy by board-certified specialists in nuclear medicine and movement disorders. Content is updated regularly to reflect the latest evidence-based guidelines and regulatory changes.
iMedic maintains strict editorial independence with no pharmaceutical company sponsorship or advertising. Our content follows peer-reviewed evidence and international medical guidelines. Read our full editorial standards.
Published: | Last reviewed: | Next review due: